Edinburgh Research Explorer

Endothelin receptor antagonism improves lipid profiles & lowers PCSK9 in patients with chronic kidney disease

Research output: Contribution to journalArticle

Standard

Endothelin receptor antagonism improves lipid profiles & lowers PCSK9 in patients with chronic kidney disease. / Farrah, Tariq; Anand, Atul; Gallacher, Peter; Kimmitt, Robert A.; Carter, Edwin; Dear, James; Mills, Nicholas; Webb, David; Dhaun, Neeraj.

In: Hypertension, 10.06.2019.

Research output: Contribution to journalArticle

Harvard

Farrah, T, Anand, A, Gallacher, P, Kimmitt, RA, Carter, E, Dear, J, Mills, N, Webb, D & Dhaun, N 2019, 'Endothelin receptor antagonism improves lipid profiles & lowers PCSK9 in patients with chronic kidney disease', Hypertension. https://doi.org/10.1161/HYPERTENSIONAHA.119.12919.

APA

Farrah, T., Anand, A., Gallacher, P., Kimmitt, R. A., Carter, E., Dear, J., ... Dhaun, N. (2019). Endothelin receptor antagonism improves lipid profiles & lowers PCSK9 in patients with chronic kidney disease. Hypertension. https://doi.org/10.1161/HYPERTENSIONAHA.119.12919.

Vancouver

Farrah T, Anand A, Gallacher P, Kimmitt RA, Carter E, Dear J et al. Endothelin receptor antagonism improves lipid profiles & lowers PCSK9 in patients with chronic kidney disease. Hypertension. 2019 Jun 10. https://doi.org/10.1161/HYPERTENSIONAHA.119.12919.

Author

Farrah, Tariq ; Anand, Atul ; Gallacher, Peter ; Kimmitt, Robert A. ; Carter, Edwin ; Dear, James ; Mills, Nicholas ; Webb, David ; Dhaun, Neeraj. / Endothelin receptor antagonism improves lipid profiles & lowers PCSK9 in patients with chronic kidney disease. In: Hypertension. 2019.